Lynch, R. C., Paneesha, S., Avigdor, A., McKinney, M. S., Wahlin, B. E., Hrom, J. S., … Trneny, M. (2021). Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients With Relapsed or Refractory Follicular Lymphoma (CITADEL-203). CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 19(1), 11–12.

Lynch, Ryan C., Shankara Paneesha, Abraham Avigdor, Matthew S. McKinney, Bjorn E. Wahlin, John S. Hrom, David Belada, et al. “Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients With Relapsed or Refractory Follicular Lymphoma (CITADEL-203).” CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY 19, no. 1 (2021): 11–12.

Lynch RC, Paneesha S, Avigdor A, McKinney MS, Wahlin BE, Hrom JS, et al. Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients With Relapsed or Refractory Follicular Lymphoma (CITADEL-203). CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY. 2021;19(1):11–2.

Lynch, Ryan C., et al. “Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients With Relapsed or Refractory Follicular Lymphoma (CITADEL-203).” CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, vol. 19, no. 1, 2021, pp. 11–12.

Lynch RC, Paneesha S, Avigdor A, McKinney MS, Wahlin BE, Hrom JS, Belada D, Canales M, Cunningham D, Devizzi L, Morley N, Zheng F, DeMarini DJ, Jiang W, Trneny M. Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients With Relapsed or Refractory Follicular Lymphoma (CITADEL-203). CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY. 2021;19(1):11–12.